Role of TGF-b1 Gene Polymorphism in Development of Multiple Myeloma

LYMPHOID TUMORS , ,

AA Pavlova1, LN Bubnova1, YuV Sokolova1, EV Karyagina2, SS Bessmel’tsev1, IE Pavlova1

1 Russian Scientific Research Institute of Hematology and Transfusiology, 16 2-ya Sovetskaya str., Saint Petersburg, Russian Federation, 191024

2 Municipal Hospital No. 15, 4 Avangardnaya str., Saint Petersburg, Russian Federation, 198205

For citation: Pavlova AA, Bubnova LN, Sokolova YuV, et al. Role of TGF-b1 Gene Polymorphism in Development of Multiple Myeloma. Clinical oncohematology. 2015;8(3):274–80 (In Russ).

ABSTRACT

Background & Aims. Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled proliferation of the clonal plasma cells. Studies showed that the TGF-b1 cytokine induces growth of the tumor clone in MM. The aim of this study was to detect single nucleotide polymorphisms (SNP) of the TGF-b gene (codon 10, codon 25) associated with the development of MM and to determine risks of the bone disease development in residents of the Northwest Russia.

Methods. 43 patients with MM were examined (mean age: 69.2 ± 9.0 years). Patients were divided into two groups: the 1st group with severe osteolytic bone lesions and the 2nd one with signs of osteoporosis and solitary foci of lysis. The control group consisted of 40 healthy donors (mean age: 49.8 ± 10.1 years).

Results. The study demonstrated that MM was associated with TGF-b1 codon 25 CC genotype and TGF-b1 codon 10/codon 25 T/C haplotype. However, the TGF-b1 codon 25 GG genotype can be considered a marker of resistance to development of MM. Osteoporosis was associated with the TGF-b1 codon 25 GG genotype, whereas the TGF-b1 codon 25 GC was detected more frequently in patients with severe osteolytic bone lesions.

Conclusion. The obtained results indicate that individual genotypes and haplotypes of TGF-b1 are involved in the formation of predisposition to development of multiple myeloma.

Keywords: multiple myeloma, cytokines, TGF-b1, single nucleotide polymorphisms.

Received: February 9, 2015

Accepted: May 30, 2015

Read in  PDF (RUS)pdficon

REFERENCES

  1. Бессмельцев С.С. Множественная миелома (патогенез, клиника, диагностика, дифференциальный диагноз). Часть I. Клиническая онкогематология. 2013;6(3):237–57.
    [Bessmel’tsev SS. Multiple myeloma (pathogenesis, clinical manifestations, diagnosis, differential diagnosis). Part I. Klinicheskaya onkogematologiya. 2013;6(3):237–57. (In Russ)]
  2. Черныш Н.Ю., Бессмельцев С.С., Козлов А.В. и др. Апоптотическая активность клеток костного мозга больных множественной миеломой. Вестник гематологии. 2009;5(3):5–11.
    [Chernysh NYu, Bessmel’tsev SS, Kozlov AV, et al. Apoptotic activity of bone marrow cells of patients with multiple myeloma. Vestnik gematologii. 2009;5(3):5–11. (In Russ)]
  3. Badros A. In the age of novel therapies, what defines high-risk multiple myeloma. J Natl Compr Canc Netw. 2010;8(Suppl 1):28–34.
  4. Свирновский А.И., Григорович С.А. Плейотропная резистентность опухолевых клеток к терапевтическим воздействиям при В-клеточных лимфопролиферативных заболеваниях. Медицинские новости. 2005;9:5–16.
    [Svirnovskii AI, Grigorovich SA. Pleiotropic resistance of tumor cells to therapeutic actions in B-cell lymphoproliferative disorders. Meditsinskie novosti. 2005;9:5–16. (In Russ)]
  5. Zheng C, Huang DR, Bergenbrant S, et al. Interleukin 6, tumour necrosis factor a, interleukin 1b and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol. 2000;109(1):39–45. doi: 10.1046/j.1365-2141.2000.01963.x.
  6. Atoum MF, Tanashat RQ, Mahmoud SA. Negative association of the HLA-DQB1*02 allele with breast cancer development among Jordanians. Asian Pacif J Cancer Prev. 2013;14(11):7007–10. doi: 10.7314/apjcp.2013.14.11.7007.
  7. Stern M, Opelz G, Dohler B, et al. Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood. 2010;115(19):3960–5. doi: 10.1182/blood-2009-10-250134.
  8. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation and cancer. J Clin Invest. 2007;117(5):1175–83. doi: 10.1172/jci31537.
  9. Landskron G, De la Fuente M, Thuwajit P, et al. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014:149185. doi: 10.1155/2014/149185.
  10. Коненков В.И., Смольникова М.В. Структурные основы и функциональная значимость аллельного полиморфизма генов цитокинов человека и их рецепторов. Медицинская иммунология. 2003;5(1–2):11–28.
    [Konenkov VI, Smol’nikova MV. Structural matrix and functional significance of allelic polymorphism of human cytokine genes and their receptors. Meditsinskaya immunologiya. 2003;5(1–2):11–28. (In Russ)]
  11. Kekik C, Besisik S, Oguz FS, et al. Determination of cytokine gene polymorphisms in Turkish patients with multiple myeloma. Adv Mol Med. 2007;3(4):189–95.
  12. Ferrarini M, Mazzoleni G, Steimberg N, et al. Innovative models to assess multiple myeloma biology and the impact of drugs. In: Hajek R, ed. Multiple myeloma – a quick reflection on the fast progress. InTech; 2013. doi: 10.5772/54312.
  13. Yasui H, Hideshima T, Anderson KC. Inhibition of TGF-b Signaling in Multiple Myeloma and Its Bone Marrow Microenvironment. In: Jakowlew SB, ed. Transforming Growth Factor-b in Cancer Therapy. Vol. II. Springer; 2008. pp. 219–27. doi: 10.1007/978-1-59745-293-9_15.
  14. Павлова А.А., Павлова И.Е., Бессмельцев С.С. Цитокины и их роль в патогенезе множественной миеломы (Обзор литературы). Medline.ru. 2013;14:313–35.
    [Pavlova AA, Pavlova IE, Bessmel’tsev SS. Cytokines and their role in pathogenesis of multiple myeloma (Literature review). Medline.ru. 2013;14:313–35. (In Russ)]
  15. Buijs JT, Stayrook KR, Guise TA. The role of TGF-b in bone metastasis: novel therapeutic perspectives. BoneKey Rep. 2012;1(6):96. doi: 10.1038/bonekey.2012.96.
  16. Matsumoto T, Abe M. TGF-b-related mechanisms of bone destruction in multiple myeloma. Bone. 2011;48(1):129–34. doi: 10.1016/j.bone.2010.05.036.
  17. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004;22(4):233–41. doi: 10.1080/08977190412331279890.
  18. Mytilineos J, Laux G, Opelz G. Relevance of IL-10, TGF-b1, TNF-a and IL-4Ra gene polymorphisms in kidney transplantation: a collaborative transplant study report. Am J Transplant. 2004;4(10):1684–90. doi: 10.1111/j.1600-6143.2004.00561.x.
  19. Banu C, Moise A, Arion CV, et al. Cytokine gene polymorphisms support diagnostic monitoring of Romanian multiple myeloma patients. J Med Life. 2011;4(3):264–8.
  20. Brown EE, Lan Q, Zheng T, et al. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer. 2007;120(12):2715–22. doi: 10.1002/ijc.22618.
  21. Барсова Р.М., Титов Б.В., Матвеева Н.А. и др. Участие гена TGFB1 в формировании предрасположенности к инфаркту миокарда. Acta Nat. 2012;4(2):76–82.
    [Barsova RM, Titov BV, Matveeva NA, et al. Involvement of the TGFB1 gene in predisposition to myocardial infarction. Acta Nat. 2012;4(2):76–82. (In Russ)]
  22. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplantation. Br J Haematol. 1998;102(5):1115–23. doi: 10.1046/j.1365-2141.1998.00930.x.
  23. Durie BGM, Harousseau J-L, San-Miguel J, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–73. doi: 10.1038/sj.leu.2404284.
  24. Бабышкина Н.Н., Малиновская Е.А., Стахеева М.Н. и др. Роль трансформирующего ростового фактора TGF-b1 в патогенезе рака молочной железы. Сибирский онкологический журнал. 2010;6(42):63–70.
    [Babyshkina NN, Malinovskaya EA, Stakheeva MN, et al. Role of transforming growth factor TGF-b1 in pathogenesis of breast cancer. Sibirskii onkologicheskii zhurnal. 2010;6(42):63–70. (In Russ)]
  25. Wrzesinnski SH, Wan YY, Flavell RA. Transforming growth factor-b and the immune response: implications for anticancer therapy. Clin Cancer Res. 2007;13(18):5262–70. doi: 10.1158/1078-0432.ccr-07-1157.